Less than 25% of patients with thyroid eye disease who underwent a full course of treatment with Tepezza required retreatment, according to a study published in Ophthalmology.
“It is becoming increasingly apparent that the [insulin-like growth factor-1 receptor] plays a key role in manifestation of the clinical signs and symptoms of [thyroid eye disease] TED,” Shoaib Ugradar, MD, of TORC-Research and lead author of the study, told Healio. “Teprotumumab addresses the unmet need for an effective medicine for TED that not only may serve as a long-term solution for most patients,